{"entity":{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","aka":["Miltenyi Biomedicine GmbH"],"tldr":"Miltenyi Biomedicine is a Germany-based cell therapy company running 5 late-stage cancer trials of zamtocabtagene autoleucel (MB-CART2019.1) and MB-CART2019.1 in diffuse large B-cell lymphoma, acute myeloid leukaemia and primary CNS lymphoma.","summary":"Miltenyi Biomedicine, based in Bergisch Gladbach, Germany, is a cell therapy company and part of Miltenyi Biotec (Miltenyi group). Develops personalised cell and gene therapies, specifically CAR-T cell therapies for oncology and autoimmune diseases; part of the Miltenyi group alongside Miltenyi Biotec. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing zamtocabtagene autoleucel (MB-CART2019.1) and MB-CART2019.1 in diffuse large B-cell lymphoma, acute myeloid leukaemia, primary CNS lymphoma and mantle cell lymphoma. The largest, NCT04792489 (DALY II USA/ MB-CART2019.1 for DLBCL), plans to enrol 315 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.miltenyibiomedicine.com"},{"label":"ClinicalTrials.gov: trials led by Miltenyi Biomedicine","url":"https://clinicaltrials.gov/search?lead=Miltenyi%20Biomedicine%20GmbH"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["dlbcl","aml","primary-cns-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["zamtocabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04792489","nct07288879","nct04844866","nct06508931"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Bergisch Gladbach","country":"DE","companyType":"cell-therapy","website":"https://www.miltenyibiomedicine.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/miltenyi-biomedicine/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/"}],"drug":[{"id":"zamtocabtagene-autoleucel","kind":"drug","name":"Zamtocabtagene autoleucel","route":"/drugs/zamtocabtagene-autoleucel/"}],"trial":[{"id":"nct07288879","kind":"trial","name":"DALY II Japan/MB-CART2019.1 for DLBCL","route":"/trials/nct07288879/"},{"id":"nct04792489","kind":"trial","name":"DALY II USA/ MB-CART2019.1 for DLBCL","route":"/trials/nct04792489/"},{"id":"nct04844866","kind":"trial","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","route":"/trials/nct04844866/"},{"id":"nct06508931","kind":"trial","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","route":"/trials/nct06508931/"}]}}